On this episode of Going There, Dr. Mike speaks with singer, songwriter, and musician Kristine Meredith Flaherty, otherwise known as the multi-platinum and Grammy-nominated artist K.Flay. You may know K.Flay from songs such as “High Enough” and “Blood in the Cut.” Her music has been described as “inimitable storytelling … personable and colorful. Neither an escape from reality nor a shun of the fantastical. Instead, it’s a playful frolic into what makes us simply human.” Be sure to check out K.Flay's new songs "Raw Raw" and "Shy," which are out now and K.Flay's new album MONO is out Sept 15th. Check out K.Flay’s music, tour info, and merch at Kflay.com. Those in need of mental health assistance can check out the Sound Mind Live resources page for a list of helplines, community programs, therapy links, and more. Listen to K.Flay talk about K.Flay's mental health journey. Also, make sure you like, review, and subscribe to Going There with Dr. Mike via your favorite podcast provider. You can also follow the Consequence Podcast Network for updates on all our shows. Season 4 of Going There with Dr. Mike is made in collaboration with Sound Mind Live and Consequence Podcast Network and is brought to you by AbbVie, who is driving the pursuit of better mental health. Over the last 30 years, AbbVie’s scientists and clinicians have worked to tackle the complexity of mental illness and today offer a portfolio of medicines and a pipeline of innovation that spans depression, anxiety, bipolar 1 disorder, and schizophrenia. To learn more about AbbVie’s work to support individuals throughout their mental health journey, please visit www.AbbVie.com or follow at AbbVie on Twitter, Facebook, Instagram, YouTube, and LinkedIn. This episode is also brought to you by Alkermes. Alkermes is a global biopharmaceutical company developing innovative medicines in the field of neuroscience with products that treat alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. To learn more, please visit Alkermes' website at www dot AL-ker-mees dot com or follow at Alkermes on Twitter and LinkedIn.